Microproteomics: Quantitative Proteomic Profiling of Small Numbers of Laser-Captured Cells

Petra L. Roulhac1,2, James M. Ward1, J. Will Thompson2, Erik J. Soderblom2, Michael Silva1, M. Arthur Moseley III2, and Erich D. Jarvis1,3

1 Department of Neurobiology, Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
2 Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27710, USA
3Corresponding authors (roulhac@neuro.duke.edu; jarvis@neuro.duke.edu).

INTRODUCTION

During the last decade, significant progress in the analysis of whole genomes and transcriptomes has triggered efforts to analyze the proteome. Advancements in protein extraction, purification, and identification have been driven by the development of mass spectrometers with greater sensitivity and resolution. Nevertheless, comparative and quantitative proteomic technologies have not progressed to the extent of genomic and transcriptomic technologies for accessing gene expression differences. Unlike the genome, which is similar throughout all cells in a given organism, the proteome varies in different cells. Also, there is no self-replicating amplification mechanism for proteins such as the polymerase chain reaction (PCR) for DNA. Therefore, developing methods that extract, separate, detect, and identify proteins from extremely small samples are needed. The advent of laser capture microdissection (LCM) has expanded the analytical capabilities of proteomics. LCM has proven an effective technique to harvest pure cell populations from tissue sections. This protocol describes a microproteomic platform that uses nanoscale liquid chromatography/tandem mass spectrometry (nano-LC-MS/MS) to simultaneously identify and quantify hundreds of proteins from LCMs of tissue sections from small tissue samples containing as few as 1000 cells. The LCM-dissected tissues are subjected to protein extraction, reduction, alkylation, and digestion, followed by injection into a nano-LC-MS/MS system for chromatographic separation and protein identification. The approach can be validated by secondary screening using immunological techniques such as immunohistochemistry or immunoblots.

RELATED INFORMATION

This protocol involves multiple stages, including tissue isolation by LCM, protein extraction and digestion, protein quantitation, protein identification, and biological verification (Fig. 1). In the following example, these techniques are used to screen for proteomic differences in two populations of brainstem motor nuclei from songbirds. These are (1) the 12th motor nucleus, which controls the syrinx muscles (i.e., the avian vocal organ), and receives a direct projection from the forebrain only in species that can imitate vocalizations; and (2) the supraspinal (SSp) motor nucleus, which controls the neck muscles (in birds and mammals), and does not receive a direct forebrain projection and thus serves as control (Jarvis 2004).

![Flowchart for microproteomic screening protocol.](http://cshprotocols.cshlp.org/cgi/content/full/2011/2/pdb.prot5573/flow1)

**FIGURE 1.** Flowchart for microproteomic screening protocol.

In this protocol, peptide sample digestos are analyzed using nanoscale capillary LC/MS/MS. The type of analysis chosen will vary widely depending on the hardware and analytical tools available. The use of high-resolution, high-mass-accuracy mass spectrometers (e.g., quadrupole/time-of-flight or Orbitrap instruments) is recommended; they allow for rigorous data collection and unbiased label-free quantitation via area-under-the-curve intensity measurements. Such systems produce highly sensitive analyses with low protein false-positive rates and accurate cross-sample quantitation (Carducci et al. 2001; Smith et al. 2002; Pačá-Toláš et al. 2004; Silva et al. 2005; Törmäcnev et al. 2008).

Individual peptides are quantified across all sample injections; integration of each chromatographic peak belonging to the same precursor mass in the aligned chromatograms is then used to calculate the peptide intensity in each LCM sample. Only data-independent mass spectrometry high energy (MS3) data are used for quantitative measurements; data-dependent acquisition (DDA) data are also aligned and used to provide supplementary protein identifications but are not used for quantitation because of the low duty cycle in the MS dimension (only one data point per ~5 sec) (Silva et al. 2006; Geromenos et al. 2009; Li et al. 2009). Relative protein quantity within each sample is calculated as the sum of the intensity of each peptide to that protein. To detect changes in protein abundance with high precision, analyze each sample in triplicate, using two MS3 quantitative/qualitative runs and one qualitative DDA run.

MATERIALS

Reagents

- Acetonitrile (Sigma-Aldrich)
Alcohol dehydrogenase digest (ADH1_YEAST; Waters)

- Ammonium bicarbonate (50 mM; Sigma-Aldrich)
- Animal of interest (for immunohistochemistry)

Antibody, primary, specific to protein of interest

Antibody, secondary, fluorescently labeled

BCA (Bicinchoninic) assay kit, low-protein (Lamda Biotech)

- Dithiothreitol (DTT, 100 mM; Sigma-Aldrich)
- Embedding medium (e.g., Tissue-Tek OCT compound; Sakura Finetek)

Ethanol (75%, 95% [both prepared with Invitrogen ultrapure water], and 100%)

Fluorescence mounting medium (e.g., VECTASHIELD; Vector Laboratories)

- Formic acid
- Iodoacetamide (200 mM; Sigma-Aldrich)
- Paraformaldehyde (4% in PBS) (Sigma-Aldrich)

Phosphate-buffered saline (PBS; 1X)

Serum, normal, species-specific

Sucrose (30% in PBS)

Tissue of interest

- Trifluoroacetic acid (TFA; Sigma-Aldrich)
- Trifluoroethanol (TFE; Sigma-Aldrich)
- Triton X-100

Trypsin, mass spectrometry grade (e.g., Trypsin Gold; Promega)

Water, distilled, ultrapure (Invitrogen)

Xylene (Sigma-Aldrich)

**Equipment**

- Chromatography column, 1.7-µm C18 BEH, 75-µm x 250-mm (Waters)
- Chromatography column, Symmetry C18, 20-µm x 180-mm (Waters)

Coverslips

Cryomolds (Sakura Finetek)

Cryostat (Leica)

Dissection tools

- Dry ice

Equipment for transcardial perfusion

- Forceps

Gloves, nitrile

Heating blocks or incubators preset to 80°C, 90°C

Lab coat

Laminar flow hood

LCM caps (e.g., CapSure Macro; Molecular Devices)

- LCM instrument (e.g., ArcturusXT; Molecular Devices)
METHOD

Wear a lab coat and nitrile gloves throughout the protocol to ensure minimal keratin contamination.

Preparation of Frozen Tissue Blocks

1. Fill the cryomold with embedding medium.

2. Prepare tissue fresh. For example, to obtain brain tissue, sacrifice the animal and rapidly dissect the brain within 5-7 min to prevent degradation of rapidly regulated proteins.

3. Place the tissue of interest in the cryomold.

4. Freeze the cryomold in an ethanol/dry ice bath; the sample will turn white within several minutes when frozen. Avoid getting ethanol into the cryomold. Tissue-Tek becomes difficult to cut when ethanol mixes with it.

5. Store the cryomold at -80°C until ready for sectioning.

Tissue Sectioning

6. Attach the frozen block of tissue to the chuck of the cryostat with embedding medium using standard frozen tissue-sectioning methods.

7. Allow the block to equilibrate to the cryostat temperature (e.g., -15°C to -20°C for brain tissue) for ~15 min.

8. Cut 10-µm sections for LCM sampling. Place the sections on a PEN membrane glass slide.

9. Store slides at -80°C until ready for LCM.

LCM

See Espina et al. (2006) and Gutstein and Morris (2007) for additional information on LCM basics. Cui et al. (2006) and Melle et al. (2009) provide information on the microdissection
of specific cellular phenotypes (e.g., various brainstem motor neurons) for subsequent mass spectrometry proteomic analyses. Although fluorescent labels can be used to identify cellular phenotypes of interest, this protocol uses unstained tissue for microdissection, which reduces the possibility of causing protein degradation or alteration resulting from tissue processing.

10. Remove the slides from the freezer. Place on dry ice to prevent protein degradation before dehydration. Proceed quickly with the following steps.

11. Dehydrate the samples by placing slides in each of the following solutions for ~45 sec per solution. Use clean forceps to transfer slides:

   Prepare the solutions fresh each day. Prepare ethanol solutions in 50-mL polypropylene tubes using RNase- and protease-free water; prepare xylene in glass vials.

   i. 75% ethanol
   ii. water
   iii. water
   iv. 75% ethanol
   v. 95% ethanol
   vi. 100% ethanol
   vii. xylene
   viii. xylene

12. Place the slides under a hood to dry for 15 min. The sample is now ready for LCM.

13. Perform LCM according to the equipment manufacturer’s instructions. The following example uses an Arcturus XT LCM system:

   i. Turn on the computer, microscope, and the microdissection instrument.
   ii. Start the software by clicking on the Arcturus XT icon.
   iii. Place sample slides and caps on the stage of the apparatus.
   iv. Open the "Load" dialog box. Select "membrane slide" and "macro caps."
   v. Locate the area of interest on the live image by moving the tracking ball.
   vi. Change the objective as needed by clicking the label corresponding to the objective of choice (e.g., phase contrast, 10x magnification).
   vii. Adjust the brightness and focus of the sample as needed.

   When using the dehydration procedure described above, neuronal cell bodies appear white against a dark neuropil background without the need for staining (Fig. 2).

   FIGURE 2. Dehydrated cryosections of adult male zebra finch brainstems mounted on a PEN membrane slide (20x; scale bar, 200 µm). Large motor neurons appear as white cell bodies against a brown neuropil background of axons and dendrites. The 12th and SSp motor nuclei are indicated. (A) Before LCM. (B) After LCM.

   viii. Select the area of interest for LCM. Click the "cut and capture" button using the ultraviolet (UV) cutting laser, the infrared (IR) capture laser, or both. The UV cutting laser provides speed and precision and is used to cut around the edges of an area of interest containing many cells; the IR capture laser is nondamaging and preserves tissue integrity.

14. After LCM, peel the membrane containing the microdissected tissue off the cap with clean forceps. Place the membrane in a glass vial. It is possible to extract protein from several LCM membranes in the same vial. The vial can be stored at -80°C until protein extraction. See Troubleshooting.

Protein Extraction and Digestion

To ensure minimal keratin contamination, perform any sample manipulation before trypsin digestion in a biological safety cabinet or laminar flow hood (i.e., Steps 15-24). See Zhang et al. (2007) for additional information on TFE protein extractions.

15. Add a 50% (v/v) mixture of 50 mM ammonium bicarbonate and TFE to the glass vial containing the LCM membrane(s) to initiate protein extraction.

16. Incubate for 10-15 min at 90°C, vortexing several times during extraction.
16. Incubate for 10-15 min at 90°C, vortexing several times during extraction. TFE will break down plastic vials over time; thus, glass vials are used for this initial step.

17. Transfer the supernatant with a pipette to a lo-bind Eppendorf tube. The LCM membrane can be discarded.

18. Concentrate the supernatant to 10 µL using a vacuum concentrator. Transfer the remaining solution to a glass vial.

19. Add 1 µL of 100 mM DTT to the solution (i.e., to a final concentration of 10 mM DTT).

20. Incubate for 15 min at 80°C to reduce the cysteine residues.


22. Add 1 µL of 200 mM iodoacetamide to the solution (i.e., to a final concentration 20 mM iodoacetamide) to alkylate the cysteine residues. Vortex the solution.

23. Incubate for 30 min at room temperature.

24. Add 45 µL of 50 mM ammonium bicarbonate, such that the total concentration of TFE is ≤5%.

25. Add ~50-100 ng of trypsin such that the ratio of trypsin:total protein is ~1:50.

26. Incubate with gentle mixing using a thermomixer overnight at 37°C.

27. Add TFA to a final concentration of 1% (v/v) to acidify the solution and inactivate trypsin.

28. Vacuum-evaporate the sample to dryness. Resuspend the sample in 25 µL of 0.1% TFA and 2% acetonitrile. The sample is now ready for LC-MS/MS analysis.

29. To perform unbiased quantitative proteomic analyses (i.e., label-free comparisons), add 100 fmol of yeast alcohol dehydrogenase digest to each sample as an internal standard for mass spectrometry analyses. To determine protein concentration, proceed with Steps 30-35. Otherwise, proceed to Step 36. Protein quantitation is preferred to normalize protein concentrations between samples. However, direct protein concentration measurements can be skipped if insufficient material is available.

**Protein Quantitation**

This procedure uses a modification of a commercially available protein assay. A heated-lid PCR thermocycler is used to prevent low-volume sample evaporation, and a NanoDrop spectrophotometer allows for spectroscopic analyses of very small volumes of dilute protein concentrations. Perform the assay on digested protein samples.

30. Prepare the BCA working solution:
   i. Mix reagents B and C from the kit in a ratio of 25:1 (v/v).
   ii. Add reagent A to the B/C mixture in a ratio of 26:1 (v/v).

31. Prepare 6-7 dilutions (0-0.1 µg/µL) of the bovine serum albumin protein standard (provided with the kit as a 2 mg/mL stock solution) in the same buffer as the samples to be assayed.

32. Add 2 µL of the protein standards or samples to individually labeled PCR tubes.

33. Add 2 µL of the BCA working solution to each protein standard and sample. Mix the contents of each tube by aspirating the solution in a pipette tip. See Troubleshooting.

34. Incubate the samples in a PCR thermocycler with a heated lid for 30 min at 60°C.

35. Measure absorbances using the NanoDrop according to the manufacturer’s instructions. The NanoDrop BCA application module plots the absorbance of each protein standard as a function of its protein concentration to generate a standard curve (which should be linear from 1 to 100 µg/µL, then uses the standard curve to calculate the protein concentration of the unknowns).
   i. Open the NanoDrop software on the computer.
   ii. Choose the BCA application module.
   iii. Initialize the instrument.
   iv. Raise the NanoDrop pedestal arm. Place 2 µL of distilled water on the analyzer. Lower the pedestal arm.
   v. Click "OK" to initialize the instrument.
   vi. Blank the instrument using 2 µL of the protein suspension buffer.
vii. Lower the pedestal arm. Click the "blank" button. The system is now ready to analyze samples.

viii. Measure the absorbance of each protein standard and unknown sample at 562 nm by placing 2 µL on the pedestal arm.

**LC-MS/MS Data Collection and Processing**

Analyze peptide digests from each LCM sample in triplicate using a nanoACQUITY UPLC system coupled to a Synapt HDMS. See Figure 3 for an example of proteomic identification results from the 12th and SSp motor nuclei of male zebra finches as determined by LC-MS/MS.

**FIGURE 3.** Qualitative proteomic screening results of the 12th and SSp motor nuclei. (A) Representative reversed-phase HPLC chromatograms of tryptic digests of proteins extracted from the 12th and SSp motor nuclei of one animal. The y-axis indicates the intensity of the peptide signal. The retention time (x-axis) represents the time it takes for a particular peptide to elute from the column and be injected onto the mass spectrometer. (B) Venn diagram showing the differences between the proteomic profiles of the 12th and SSp motor nuclei across six animals.

36. Separate the peptide fragments:
   i. Load ~250 ng of a digested peptide sample in 8 µL on a 20-µm x 180-mm Symmetry C18 column by running at 20 µL/min for 2 min using water/formic acid (99.9:0.1 [v/v]).
   ii. Separate peptide fragments on a 75-µm x 250-mm C18 BEH column using a 90-min gradient of 5%-40% acetonitrile with 0.1% formic acid at a flow rate of 0.3 µL/min and a column temperature of 45°C.

37. Perform two MS² analyses per sample for simultaneous peptide quantification and identification:
   i. Introduce samples directly into the mass spectrometer via electrospray ionization.
   ii. Use a 0.9-sec cycle time, alternating between low-collision energy (6 V) and a high-collision energy ramp (15-40 V).

38. In addition to quantitative analyses, perform an additional LC-MS/MS analysis in the DDA acquisition mode for each sample for complementary peptide identifications:
   i. Perform a 0.9-sec MS scan.
   ii. Perform an MS/MS acquisition on the top three ions with charges >1 using an isolation window of ~3 Da, a maximum of 4 sec per precursor, and dynamic exclusion for 120 sec within 1.2 Da.

**LC-MS/MS Data Processing**

This method processes LC-MS/MS data using a label-free quantitative pipeline.

39. Use LC-MS/MS data processing software for raw data alignment, feature identification, and feature extraction. Use the manufacturer’s default settings, with the exception of the lockmass correction.
   The lockmass correction for the quadropole/time-of-flight data is the (M + 2H)²⁺ ion of Glu-Fibrinopeptide B, 785.8426 m/z.
   See Troubleshooting.

40. Use the MS² and DDA data to generate peptide identifications:
   Set the precursor ion mass tolerance at 20 ppm for both the Mascot and PLGS searches. Use a product ion tolerance of 0.04 Da for Mascot and 40 ppm for PLGS.
   For DDA files
   i. Produce searchable .mgf files using Rosetta Elucidator.
   ii. Use the Mascot v2.2 search engine to search a database of vertebrate proteins (in the example here, including zebra finch) in an automated fashion.
   For the MS² data
   iii. Use PLGS to generate searchable files using default settings.

41. Search the DDA and MS² annotated data against the relevant databases.
   For the example here, data were searched against the NCBIRef database [http://www.protein.sdu.dk/gpmaaw/GPMAW/Database/NCRBRef/nchirp.html] containing the zebra finch predicted protein sequences from Ensembl (downloaded March 4, 2009) and the Songbird Brain Transcriptome Database [http://songbirdtranscriptome.net/]. The Ensembl and the Songbird Brain Transcriptome databases were modified to contain a full 1x reverse database appended for peptide false discovery rate (FDR) determination. See Wada et al. (2006) and Warren et al. (2010) for additional information on the Jarvis Laboratory transcriptome database and the songbird genome.
42. Use Protein Digestion Simulator Basic ([http://omics.pnl.gov/software/ProteinDigestionSimulatorBasic.php](http://omics.pnl.gov/software/ProteinDigestionSimulatorBasic.php)) to remove duplicates from your database of interest. Include carbamidomethyl cysteine as a fixed modification and oxidized methionine as a variable modification.

43. Import results from your search engines of interest back into Elucidator. Concurrently validate the results with the PeptideTeller and ProteinTeller algorithms using independent decoy database validation and peptides annotated at a 1% peptide FDR.

44. Add the intensities of peptides annotated to the same protein to gain a measure of the relative protein abundance between samples. Use only the MS² data for quantitative measurements. Because of the way Elucidator aligns data across samples, it uses the same number of peptides for the purpose of quantitation in every sample.

**LC-MS/MS Data Analysis**

45. Normalize signal intensities across peptides (Fig. 4):

![FIGURE 4. Quantitative technical replicate profiles across all samples from one experiment. (A) Raw intensity of technical replicates 1 and 2 from the average LC-MS signal of all peptides in the paired samples of the motor nuclei of each animal. (The SSp sample from Bird 6 was eliminated because protein extraction difficulties resulted in limited protein identifications.) Data points are expressed as mean log₂ intensity. (B) Intensity of each data point normalized to the cross-sample median distribution.](image)

i. Obtain the absolute quantity of peptides observed for each Ensembl-predicted protein as determined by the Mascot software tool. Convert all quantities to a log₂ scale to scale fold differences.

ii. Take the subset of data for peptides that are detected in 90% of all samples and whose log₂ median expression is higher than the lower 25th percentile for all data.

iii. Prepare median-centered data by calculating the median log₂ quantity of each peptide. Subtract this value from the log₂ measurements by peptide.

iv. For each sample, calculate the distribution of log₂ median-centered values in 100 steps (such that each step represents one percentage point in the quantile distribution).

v. Calculate the median profile by taking the median for each step across all samples.

vi. For each sample, calculate the difference from the median profile at each step in the distribution.

vii. Plot each profile using the “steps” as the x-axis and the log₂ difference as the y-axis. Confirm that the central regions of each profile are relatively horizontal and parallel to one another. The spread of profiles above and below 1 at the 50th percentile is roughly the effect of the normalization to be applied below.

viii. Generate a log₂ normalization factor for each sample by taking the mean of the collective 40-60 steps from each sample’s median log₂ differences as plotted above.

ix. Normalize each sample by subtracting the log₂ normalization factor from each log₂ quantity for that sample. Peptide quantities should now be normalized to a common median reference as defined by the samples being used.

46. Use biostatistical methods to compare sample groups using the normalized log₂ quantities:

i. Use statistical software to perform paired t-tests for each peptide.

ii. Apply a Storey’s Q-value adjustment for each peptide to correct for the presence of many variables (peptides).

47. Select proteins identified as differentially expressed for validation by immunohistochemistry based on at least two to three criteria. When dealing with two tissue regions from the same subject/animal, a paired approach is advised, for example, a paired t-test. If the number of replicates differs between sample groups, an unpaired t-test is advised. When dealing with more than two samples or other variables, an analysis of variance (ANOVA) is advised, assuming the data are normally distributed.

i. Unadjusted paired t-test P-value <0.01 and Q-value <0.2

ii. Quantitative differentially expressed proteins replicated in independent experiments (see Fig. 5)
iii. When multiple peptides are detected, they are differentially expressed in the same direction with similar statistical values. *This last criterion must be handled with caution because one peptide could be differentially expressed, whereas another representing a different isoform is not.*

**Biological Validation by Immunohistochemistry**

*Biological validations can be performed with immunohistochemistry or immunoblots. Immunohistochemistry is useful for determining the number of labeled cells and is the preferred means for secondary screening because it provides anatomical resolution and requires very little tissue (e.g., thin sections). An immunoblot of specific brain regions provides more quantitative information on expression levels and molecular weights, but requires significant amounts of protein. If sufficient material is available, it is useful to perform both.*

48. Perfuse an animal transcardially with PBS for 10 min.

49. Perfuse the animal transcardially with 4% paraformaldehyde for 30 min.

50. Dissect the tissue of interest. Postfix in 4% paraformaldehyde for 2 h.

51. Transfer tissue to a polyethylene tube containing 30% sucrose. Incubate overnight at 4°C. *The tissue will sink to the bottom of the tube.*

52. Embed the tissue in a block mold with embedding medium in a dry ice/ethanol bath.

53. Cut 40-µm sections using a cryostat. Float the sections on PBS in a multiwell plate. *Tissue-Tek will dissolve in PBS.*

54. Rinse the sections in PBS three times for 5 min each.

55. Incubate the sections in a blocking solution of PBS containing 0.3% Triton X and 5% species-specific normal serum for 30 min at room temperature.

56. Incubate the sections overnight at 4°C in a PBS solution containing 0.3% Triton X and the primary antibody of interest.

57. The following day, wash the sections in PBS three times for 5 min each.

58. Incubate the sections in a PBS solution containing the appropriate fluorescent secondary antibody for 2 h at room temperature.

59. After staining, rinse the tissue in PBS. Mount onto glass slides.

60. Allow the slides to air-dry. Coverslip the slides with VECTASHIELD.

61. Observe the immunolabel under a fluorescence microscope to verify and quantify differential expression.

**TROUBLESHOOTING**

**Problem:** In LCM, cells do not adhere to the CapSure cap.

[Step 14]

**Solution:** Ensure that the tissue is properly dehydrated. If the tissue section has folds, try a different section or set the cap in a region away from the folds. Tissue that is folded is not suitable for LCM.

**Problem:** Protein unknowns change color rapidly (dark purple) after the addition of BCA working solution.

[Step 33]

**Solution:** Reducing agents such as DTT in concentrations >1 mM interfere with the assay. Dilute the unknowns enough to lower the interference caused by DTT. Be sure to check the effect on the standard curve assayed in the same buffer as the unknown samples.

**Problem:** There is polypropylene contamination, denoted by intense +44 Da repeats in the LC-MS/MS chromatograph.

[Step 39]
**DISCUSSION**

Here we developed a comparative microproteomics approach using LCM and gel-free mass spectrometry that can detect and identify hundreds of proteins from fewer than 1000 cells. Relative to high-throughput technologies for assessing gene expression differences between experimental samples (e.g., microarrays, deep sequencing), comparative proteomic technologies are limited by sensitivity and reproducibility (Anderson and Grant 2006; Gygi et al. 2008). Historically, quantitative proteomic studies have typically relied on two-dimensional difference gel electrophoresis (2D-DIGE) for the separation and visualization of experimental and control samples. 2D-DIGE has been used successfully to detect changes in relative abundance of visualized proteins, various protein isoforms, and post-translational modifications (Merkley et al. 2009; Stephens et al. 2010; Tumani et al. 2010). However, although 2D-DIGE can detect up to approximately 1500 protein spots in a given sample, these spots subsequently must be isolated and identified by a different method, typically mass spectrometry. The disconnect between the expression measurement and protein identification is limited by low throughput, and protein identification is restricted to proteins that show differential expression between two or more states. Also, results can be ambiguous for gel spots where multiple proteins are identified.

Over the last decade, as a complement to gel-based proteomics, several quantitative gel-free proteomic techniques have been developed (Gygi et al. 1999; Olsen et al. 2004; Haagani et al. 2007). Gel-free approaches use liquid chromatography coupled to tandem mass spectrometry to separate and identify peptides having various physicochemical properties obtained from the elution of digest protein extracts, and allows for the simultaneous identification and quantification of proteins. As such, gel-free mass-spectrometry-based techniques have enhanced the range (i.e., the number of protein identifications) and reliability of quantitative proteomic data.

With the advent of LCM, the analytical capabilities of comparative proteomic technologies have improved dramatically. Recently, 2D-DIGE and quantitative gel-free mass spectrometry approaches have been coupled to LCM for proteomic analyses of distinct, pure cell populations (Shokouh et al. 2003; Li et al. 2004; Zang et al. 2004; Haagani et al. 2005; Bagnato et al. 2007; Mustafa et al. 2008; Patel et al. 2008; Wang et al. 2008; Zhang and Koay 2008; Nan et al. 2009; Scicchitano et al. 2009; Waanders et al. 2009; Yao et al. 2009; Atsumia et al. 2010; Zhang et al. 2010). Other methods such as punch biopsy can be used to microdissect tissues for subsequent proteomic analyses (Folli et al. 2010), but because it is difficult to see the three-dimensional boundaries of structures from the surface of the tissue, punch biopsies can sample adjacent regions that are not of interest. Also, tissues of interest do not necessarily have circular shapes, making punch biopsy less effective. Thus, although tissue obtained from punch biopsy can be used in the protocol presented here, LCM is more precise. Further developments in LCM technology should enable effective sampling of specific cellular subtypes from tissue in a high-throughput manner.

Previous studies typically quantified protein expression from tissues containing tens of thousands of cells. The miniaturization of extraction and quantification technologies described here expands the analytical capabilities of comparative proteomics; the procedure is optimized to isolate and detect hundreds of proteins (100-300 proteins) from different cell populations containing as few as 1000 cells. Additionally, it can detect and verify robust protein expression differences between different cell populations (see Fig. 5, Fig. 6). Unlike traditional proteomic technologies such as SDS-PAGE with mass spectrometry identification or 2D-DIGE, which require at least 10-50 µg of protein (Shokouh et al. 2007; Pinaud et al. 2008), this procedure requires 1-2 µg of protein. However, each step of the procedure requires greater care as the sample size decreases. Protein losses during extraction and separation become more significant as the protein detection limit (<0.75 µg) is approached. It also becomes more difficult to evaluate differences between two samples with small amounts of protein because the variability increases as one operates closer to the limits of detection of the analytical technique. Our technique addresses the quantitation issues associated with very small protein concentrations. Although commercially available protein assays can reliably quantify protein concentrations ranging from 20 to 2000 µg/mL, they often require large volumes of concentrated protein samples. The modified procedure described here can reliably quantify small volumes of dilute protein concentrations in the 1-100 µg/mL range.

**FIGURE 6.** Immunohistochemical validation of calretinin expression in the 12th and SSp motor nuclei. (A) Darkfield coronal section of male zebra finch brainstem. (B) The same section as in A under fluorescence imaging shows calretinin expression (green) detected by a fluorescein isothiocyanate (FITC)-labeled calretinin-specific antibody. (C) Quantitative analysis of calretinin-expressing cells. The total number of motor neurons was determined from darkfield images; the number of calretinin-labeled neurons was determined from FITC fluorescence images. There are nine times as many calretinin-positive neurons in the SSp motor nucleus as there are in the 12th motor nucleus (n = 3; [*] p < 0.003). Scale bars, 500 µm.

In the example presented here, this protocol was used to screen for proteomic differences potentially involved in vocal learning in songbirds. Vocal learning is the ability to acquire vocalizations through imitation and is a critical behavioral substrate for spoken human language (Jarvis 2004). Molecular differences at the protein level might control the maintenance of the forebrain-to-brainstem projection in vocal learning avian species. The 12th motor nucleus controls the syrinx muscles and receives a direct forebrain projection in vocal learning species (e.g., songbirds, parrots, hummingbirds) (Jarvis 2004), whereas the SSp motor nucleus controls the neck muscles and does not receive a direct forebrain projection in either vocal learner or vocal nonlearner avian species. Similar findings have been demonstrated in mammals, including vocal learning humans versus vocal nonlearning nonhuman primates (Jarvis 2004; Jürgens 2009). A comparison of the proteomic differences between these nuclei from six adult male zebra finches identified and quantified 245 proteins. Future work will involve manipulation of the differentially regulated proteins.

**ACKNOWLEDGMENTS**

We thank Dr. Oscar Alzate for discussions in the initial stages of the development of the microproteomics protocols, Erina Hara for assistance with immunohistochemistry, Dr. Miriam Rivas for LCM training, and Holly Wantuch for animal husbandry. Development of this protocol was supported by the National Institutes of Health (NIH) Director’s Pioneer Award and Howard Hughes Medical Institute (HHMI) to E.D.J. and a National Institute of Neurological Disorders and Stroke (NINDS) postdoctoral translational T32 grant to P.L.R.

**REFERENCES**


Smith RD, Anderson GA, Lipton MS, Pa... histochemistry.


